Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. develops and commercializes regenerative biomaterial products for wound care, burn and surgical applications. Its updates center on placental allografts and related advanced wound care technologies, including AMNIOFIX, CHORIOFIX and G4Derm Plus, as the company adds product configurations, distribution rights and clinical evidence for complex wound management.
Company news also covers operating results for the Wound and Surgical businesses, reimbursement-driven market conditions, cost-reduction actions, investor presentations, conference participation and capital actions such as share repurchase authorization.
MiMedx Group, Inc. (Nasdaq: MDXG) has appointed Kate Surdez as the new Chief Human Resources Officer (CHRO), effective July 18, 2022. With over 20 years of HR experience, Surdez has successfully led initiatives in talent acquisition and organizational change for major biotech companies. CEO Timothy Wright expressed confidence in Surdez's ability to enhance the company's talent strategies and alignment with business goals. MiMedx specializes in placental biologics, focusing on innovative treatments for chronic wounds and musculoskeletal conditions.
MIMEDX Group announced a collaboration with Nordic Bioscience Clinical Development to advance its knee osteoarthritis clinical trial program. Image Analysis Group will provide advanced imaging analytics to assess mdHACM as a potential Disease Modifying Osteoarthritis Drug (DMOAD). The registrational trial will use WOMAC Pain and Function as co-primary endpoints. Previous Phase 2B study results showed significant improvement in pain and function metrics. MIMEDX aims to address product potency issues observed in earlier studies to ensure robust efficacy in future trials.
Prescience Point Capital Management, holding approximately 6.7% of MiMedx Group's shares (MDXG), expresses discontent following the company's recent annual meeting. A significant share of non-affiliated voters opposed the re-election of incumbent directors James Bierman and Phyllis Gardner, with 56% and 49% voting WITHHOLD/ABSTAIN, respectively. Additionally, 79% rejected the executive compensation proposal. Prescience Point demands accountability and highlights a disconnect between share price and company value, urging MiMedx leadership to address these concerns or face potential shareholder actions in the next election.
Mariietta, GA, June 7, 2022 - MiMedx Group (NASDAQ: MDXG) announced the reelection of directors Dr. Phyllis Gardner and James L. Bierman during the 2022 Annual Meeting of Shareholders. Shareholders approved all proposals, including the Say-on-Pay and Qualified Employee Stock Purchase Plan. Chair of the Board, Dr. M. Kathleen Behrens, emphasized the Company’s commitment to growth and responsiveness to shareholder feedback on executive compensation. Final voting results will be filed with the SEC.
Prescience Point Capital Management, holding approximately 6.7% of MiMedx Group (MDXG), has expressed concerns over the lack of transparency regarding preliminary voting results from the company's recent annual meeting. The firm suspects that a significant number of shares voted against the re-election of directors and executive compensation proposals. Founder Eiad Asbahi urges MiMedx to disclose voting results to confirm shareholder sentiment. The firm believes that discontent among non-affiliated shareholders could prompt management to prioritize broader shareholder interests.
Marietta, Ga. – MiMedx Group, Inc. (NASDAQ: MDXG) has announced that shareholders must pre-register by 9:00 a.m. Eastern Time on June 6, 2022, to attend its 2022 Annual Meeting of Shareholders, scheduled for June 7, 2022, at 9:00 a.m. Eastern Time. The meeting will be virtual, allowing shareholders of record as of April 11, 2022, to vote. More details and registration instructions are available at www.votemimedx.com. MiMedx specializes in placental biologics for healthcare, focusing on non-healing wounds and musculoskeletal conditions.
MiMedx Group, Inc. (NASDAQ: MDXG) urges shareholders to support its independent directors in the upcoming vote, addressing misrepresentations by Prescience Point. The company emphasizes its strategic focus on long-term shareholder value, highlighting executive compensation aligned with performance and the significant role of EW Healthcare as a major shareholder. MIMEDX details its advancements in R&D and manufacturing, as well as the successful handling of clinical trial challenges. The 2022 Annual Meeting is set for June 7, 2022, where shareholders can vote via the WHITE proxy card.
MiMedx Group, Inc. (MDXG) has urged shareholders to vote in favor of its nominated directors, James L. Bierman and Phyllis Gardner, during the upcoming 2022 Annual Meeting scheduled for June 7, 2022. The Board emphasizes the significant transformation the company has undergone, overcoming financial challenges and restructuring its management team. New compensation programs have been introduced to align with growth objectives. The letter from Board Chair Dr. M. Kathleen Behrens highlights the company's progress and encourages shareholder participation in the voting process to ensure continued growth.
Prescience Point Capital Management, owning 6.7% of MiMedx Group's stock (MDXG), announced it will WITHHOLD votes against directors Phyllis Gardner and James Bierman during the June 7, 2022, annual meeting. The firm criticized the board for mismanagement, highlighting a 60% drop in share price due to failed clinical trials caused by expired products. Moreover, Prescience Point opposes executive compensation, alleging self-serving actions benefiting the board and EW Healthcare Partners over shareholders. They urged management to buy shares to align with shareholders' interests.
Mimedx Group, Inc. (MDXG) has secured a $4.6 million award to evaluate the PURION processed Dehydrated Human Amnion Chorion Membrane (DHACM) for treating combat wounds and burns. Sponsored by the Medical Technology Enterprise Consortium (MTEC) and the U.S. Army, the funding aims to improve outcomes for military personnel facing acute injuries. Clinical trials will be led by the University of Arizona and University of Miami, focusing on the safety and efficacy of DHACM. This initiative underscores a commitment to addressing critical medical needs in military settings.